Harvard Bioscience
HBIO
69 hedge funds and large institutions have $60.6M invested in Harvard Bioscience in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 15 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
7% less capital invested
Capital invested by funds: $65.1M → $60.6M (-$4.49M)
15% less funds holding
Funds holding: 81 → 69 (-12)
80% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.36M |
| 2 |
GPC
Glacier Peak Capital
Bellevue,
Washington
|
+$573K |
| 3 |
RA
Royce & Associates
New York
|
+$319K |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$278K |
| 5 |
PCMI
Paradigm Capital Management Inc
Albany,
New York
|
+$264K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$1.64M |
| 2 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
-$783K |
| 3 |
TA
Teton Advisors
Rye,
New York
|
-$447K |
| 4 |
Millennium Management
New York
|
-$433K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$359K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
76
Credit Suisse
Zurich,
Switzerland
| – | -$173K | -6,064 | Closed |
|
|
SB
77
Suntrust Banks
Atlanta,
Georgia
| – | -$171K | -5,985 | Closed |
|
78
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$103K | -3,712 | -100% |
|
|
LP
79
LMR Partners
London,
United Kingdom
| – | -$78K | -2,720 | Closed |
|
|
AGM
80
Alpine Global Management
New York
| – | -$71K | -2,478 | Closed |
|
81
Jane Street
New York
| – | -$57K | -2,001 | Closed |
|
|
OAM
82
Oxford Asset Management
Oxford,
United Kingdom
| – | -$35K | -1,239 | Closed |
|
83
Squarepoint
New York
| – | -$32K | -1,120 | Closed |
|
|
JC
84
JBF Capital
Aspen,
Colorado
| – | -$18K | -620 | Closed |
|
85
Barclays
London,
United Kingdom
| – | -$8K | -285 | Closed |
|
HBIO Hedge Fund Activity: Q3 2016 in Review
69 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q3 2016, worth a combined $60.6M — down 6.9% from $65.1M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of HBIO and 3 opened new positions — a net loss of 12 holders — while 22 trimmed existing stakes and 28 added.
The largest buyer was Kennedy Capital Management, opening a new position worth an estimated $1.36M. The largest seller was Polar Asset Management Partners, cutting an estimated $1.64M.
- 69 institutional investors held Harvard Bioscience (HBIO) as of Q3 2016, down from 81 in Q2 2016.
- Funds reported $60.6M of Harvard Bioscience stock for Q3 2016, down 6.9% quarter-over-quarter.
- 3 funds opened new Harvard Bioscience positions in Q3 2016 and 15 closed out, a net change of -12 holders.
- The largest Harvard Bioscience buyer in Q3 2016 was Kennedy Capital Management, an estimated $1.36M added.
- The largest Harvard Bioscience seller in Q3 2016 was Polar Asset Management Partners, an estimated $1.64M sold.
Based on aggregated 13F filings for Q3 2016.